The Benefit of Treating Lung Cancer with Immunotherapy

Findings from the TROPION-Lung04 study were presented at the ESMO Targeted Anticancer Therapies Congress 2025 in March.

In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.

In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.

The field of cancer research and treatment is, almost by definition, continually evolving.

Trials of IFx-Hu2.0 are initiating, looking to overcome checkpoint inhibitor resistance in Merkel cell carcinoma.